Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib plus PD-1 inhibitors as first-line treatment for unresectable biliary tract cancer
ChiCTR2100044476Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib in biliary cancer, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: Objective response rate, Conversion surgery rate and 1 more. Started Mar 2018; status: recruiting.
02
Drugs
lenvatinib
03
Conditions
biliary cancer
Beyond the preview
Go deeper on ChiCTR2100044476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044476.